Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure

Archives of Internal Medicine

Volumn 169, Issue 2, 2009, Pages 141-149

  Gislason, Gunnar H ^a   Rasmussen, Jeppe N ^b   Abildstrom, Steen Z ^a,b   Schramm, Tina K ^a,b   Hansen, Morten L ^a   Fosbøl, Emil L ^a   Sørensen, Rikke ^a   Folke, Fredrik ^a   Buch, Pernille ^a   Gadsbøll, Niels ^e   Rasmussen, Søren ^b   Poulsen, Henrik E ^b,c   Køber, Lars ^b,c   Madsen, Mette ^d   Torp Pedersen, Christian ^a,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e KØGE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LOOP DIURETIC AGENT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SPIRONOLACTONE;

ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE ASSOCIATION; DISEASE REGISTRY; DISEASE SEVERITY; DRUG FATALITY; DRUG USE; FEMALE; HEART DEATH; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SAMPLE SIZE;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 58849157666     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2008.525     Document Type: Article

References (46)

1. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):1520-1528.
2. Mukherjee D, Nissen SE,Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954-959.
3. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004; 364(9450):2021-2029.
4. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475-481.
5. Solomon SD, McMurray JJ, Pfeffer MA, et al; Adenoma Prevention with Cele-coxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352 (11):1071-1080.
6. Bresalier RS, Sandler RS, Quan H, et al; Adenomatous Polyp Prevention on Vi-oxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352 (11):1092-1102.
7. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005; 352(11):1081-1091.
8. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. BMJ. 2005;330(7504):1366-1373.
9. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005;165(9):978-984.
10. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselectivev nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906-2913.
11. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):1633-1644.
12. Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005; 46(6):e1-e82.
13. Swedberg K, Cleland J, Dargie H, et al; Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26(11):1115-1140.
14. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H,Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634-1642.
15. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation. 2007;116(7):737-744.
16. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins afteracute myocardial infarction. Eur Heart J. 2006;27(10):1153-1158.
17. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97(12):1759-1764.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
19. Nuttall M, van der Meulen J, Emberton M. Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing uro-logical cancer surgery. J Clin Epidemiol. 2006;59(3):265-273.
20. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144-153.
21. Solomon SD, Pfeffer MA, McMurray JJ, et al; APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114(10):1028-1035.
22. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1(7):e33.
23. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal antiinflamma- tory drugs increase the risk of atherothrombosis? meta-analysis of randomised trials. BMJ. 2006;332(7553):1302-1308.
24. Pfizer. PRECISION: Prospective randomized evaluation of celecoxib integrated safety vs ilbuprofen or naproxen. http://clinicaltrials.gov/show/ NCT00346216. Accessed July 1, 2007.
25. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005;112(5):759-770.
26. Fries S, Grosser T, Price TS, et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology. 2006;130(1):55-64.
27. Brophy JM, Lévesque LE, Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart. 2007;93(2):189-194.
28. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal antiinflammatory drugs: population based study. BMJ. 2005;330(7504):1370- 1376.
29. Huerta C, Varas-Lorenzo C, Castellsague J, García Rodríguez LA. Non-steroidal antiinflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart. 2006;92(11):1610- 1615.
30. Aw T-J, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165(5):490-496.
31. Francois H, Athirakul K, Howell D, et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab. 2005;2(3):201-207.
32. Timmers L, Sluijter JPG, Verlaan CWJ, et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation. 2007;115(3):326-332.
33. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with cele-coxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study, a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247-1255.
34. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J. 2006;27(14):1657-1663.
35. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus nonselective non-steroidal antiinflammatory drugs and congestive heartfailure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363 (9423):1751-1756.
36. Hudson M, Rahme E, Richard H, Pilote L. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective cyclooxygenase 2 inhibitors: a class effect? Arthritis Rheum. 2007;57(3):516-523.
37. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002;162(10):1099- 1104.
38. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 2002;162(10):1111-1115.
39. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162(10):1105-1110.
40. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817.
41. Hudson M, Baron M, Rahme E, Pilote L. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction [published correction appears in J Rheumatol. 2005;32(11):2280]. J Rheumatol. 2005; 32(8):1589-1593.
42. Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high-risk patients with osteoarthritis treated with ibuprofen, naproxen, or lumiracoxib. Ann Rheum Dis. 2007;66(6):764-770.
43. Levesque LE, Brophy JM, Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ. 2006;174(11):1563-1569.
44. Kümler T, Gislason GH, Kirk V, et al. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail. 2008;10(7):658-660.
45. Lee DS, Donovan L, Austin PC, et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005;43(2):182-188.
46. GrosserT, Fries S, FitzGerald GA. Biological basis forthe cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4-15.